60 Degrees Pharmaceuticals, Inc. SXTP
Regular-session close
After hours · Nov 19, 5:24 PM ET
- YTD
- -75.37%
- 1 year
- -88.10%
5D +0.0232 (+4.59%)
- Market cap
- 2.24M
- Revenue (ttm)
- 441.25K
- EPS (ttm)
- -5.34
- Shares out
- 2.30M
- Forward P/E
- -0.65
- YTD return
- -75.37%
- 1-year return
- -88.10%
- 50-day average
- 1.09
- Volume
- 22.28K
- Avg volume
- 406.73K
- Open
- 0.50
- Previous close
- 0.5379
- Day's range
- 0.50 – 0.5165
- 52-week range
- 0.46 – 8.62
- Analysts
- Buy
- Price target
- 3.40 (+580.0%)
Key statistics
- 200-day average
- 2.14
- Enterprise value
- 9.95M
- Price / sales
- 6.04
- Revenue growth
- 100.60%
- Free cash flow
- -1.06M
- Total cash
- 1.58M
- Total debt
- 157.44K
- Short % of float
- 2.12%
Fundamental scorecard
4 of 25 checks passed on SXTP’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.60 | -0.93 | -0.33 | -55.00% |
| Aug 14, 2024 | Jun 1, 2024 | -3.96 | -4.23 | -0.27 | -6.82% |
| Aug 14, 2024 | Jun 1, 2024 | -3.96 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -1.92 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -1.92 | 0.36 | +2.28 | +118.75% |
| Apr 1, 2024 | Dec 1, 2023 | -3.24 | -5.28 | -2.04 | -62.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Dec 11, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 15, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Sep 13, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Jun 6, 2024 | HC Wainwright & Co. | reit | — | Neutral |
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- 60degreespharma.com
News
60 Degrees Q3 EPS $(0.75) Misses $(0.73) Estimate, Sales $233.235K Miss $300.000K Estimate
Critical Survey: GSK (NYSE:GSK) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP) 60 Degrees Pharmaceutical Enters Sponsored Research Agreement With University Of Southern Mississippi To Assess The Potential Of Castanospermine In Nonclinical Models Of Alpha-Gal Syndrome
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 60 Degrees Pharma Reports Clinical, Molecular Results From First Five Completed Patients In Relapsing Babesiosis Expanded Access Study; All Five Completed Patients Report Clinical Improvement
Your note
Sign in to keep a note on SXTP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN CHARLES W | Director | Conversion of Exercise of derivative security | May 15, 2024 | 14,000 |
| DOW GEOFFREY S | Chief Executive Officer | Conversion of Exercise of derivative security | May 15, 2024 | 762,625 |
| FIELD PAUL | Director | Conversion of Exercise of derivative security | May 15, 2024 | 14,000 |
| KNIGHT THERAPEUTICS, INC. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 27, 2023 | 0 |
| MILLER TYRONE | Chief Financial Officer | Stock Award(Grant) | May 15, 2024 | 176,928 |
| TOOVEY STEPHEN | Director | Stock Award(Grant) | May 15, 2024 | 14,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Virtu Financial LLC | 0.55% | 12,678 | 14.71K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.44% | 10,095 | 11.71K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.17% | 4,000 | 4.64K | Sep 29, 2024 |
| UBS Group AG | 0.14% | 3,311 | 3.84K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.06% | 1,473 | 1.71K | Sep 29, 2024 |
| Safe Harbor Fiduciary, LLC | 0.06% | 1,375 | 1.59K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.17% | 3,875 | 4.49K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 2,137 | 2.48K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.03% | 588 | 682 | Sep 29, 2024 |
